Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
≥18 years of age;
Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;
Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the "Other" subtype;
Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;
Patients who meet any of the following criteria will be excluded from the study：
Currently enrolled in another clinical trial；
Received prior lymphoma treatment with alternative regimens before enrollment;
Presence of concurrent malignant tumors;
Single group
Chidamide plus R-CHOP
DrugChidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)
PFS
from date of inclusion to date of progression, relapse, or death from any cause
CR rate
complete remission rate
OS
Overall Survival: from the date of inclusion to date of death, irrespective of cause
ORR
The Overall Response Rate
Click on the lead sponsor to view all of their trials.
